Menu
1 min read · estimated
APPROVED USE
What FDA approved
For children older than one month with NTRK fusion-positive solid tumors without a known acquired resistance mutation. Tumors must be metastatic or resection likely to cause severe morbidity, with progression after treatment or no satisfactory standard therapy.
LAMPGEN ANALYSIS
Why it matters
The expanded accelerated approval reached younger children, and the FDA also approved an oral pellet formulation.
What research teams should watch
Verify age, fusion and resistance status, then match the formulation to the child's administration needs.
PRIMARY RECORDS